Literature DB >> 15963492

Nicotinic receptors regulate B lymphocyte activation and immune response.

Marina Skok1, Régis Grailhe, Jean-Pierre Changeux.   

Abstract

The presence of nicotinic acetylcholine receptors (nicotinic receptors) composed of either alpha7 or alpha4 and beta2 subunits is revealed in B lymphocytes by means of radioligand binding assay and Cell ELISA. Mouse B lymphocytes contained 12,200+/-3200 of epibatidine-binding sites and 3130+/-750 of alpha-Bungarotoxin-binding sites per cell. Mice lacking nicotinic receptor subunits alpha4, beta2 or alpha7 had less serum IgG and IgG-producing cells in the spleen, but showed stronger immune response to both protein antigen in vivo and CD40-specific antibody in vitro than wild-type mice. Anti-CD40-stimulated proliferation of B lymphocytes from beta2 knockout, but not wild-type mice was inhibited with nicotine. Our results indicate that signalling through nicotinic receptors affects both the pre-immune state and activation of B lymphocytes in the immune response, possibly via CD40-dependent pathway. This could contribute to immune depression found in tobacco smokers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963492     DOI: 10.1016/j.ejphar.2005.05.011

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  30 in total

1.  Neural signaling in the spleen controls B-cell responses to blood-borne antigen.

Authors:  Paola Mina-Osorio; Mauricio Rosas-Ballina; Sergio I Valdes-Ferrer; Yousef Al-Abed; Kevin J Tracey; Betty Diamond
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 2.  Neuroimmune Communication in Health and Disease.

Authors:  Colin Reardon; Kaitlin Murray; Alan E Lomax
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

Review 3.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

Review 4.  Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.

Authors:  Namrita Halder; Girdhari Lal
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

5.  Impact of female cigarette smoking on circulating B cells in vivo: the suppressed ICOSLG, TCF3, and VCAM1 gene functional network may inhibit normal cell function.

Authors:  Feng Pan; Tie-Lin Yang; Xiang-Ding Chen; Yuan Chen; Ge Gao; Yao-Zhong Liu; Yu-Fang Pei; Bao-Yong Sha; Yan Jiang; Chao Xu; Robert R Recker; Hong-Wen Deng
Journal:  Immunogenetics       Date:  2010-03-09       Impact factor: 2.846

6.  Auto/paracrine control of inflammatory cytokines by acetylcholine in macrophage-like U937 cells through nicotinic receptors.

Authors:  Alexander I Chernyavsky; Juan Arredondo; Maryna Skok; Sergei A Grando
Journal:  Int Immunopharmacol       Date:  2009-12-18       Impact factor: 4.932

Review 7.  Nicotine and inflammatory neurological disorders.

Authors:  Wen-Hua Piao; Denise Campagnolo; Carlos Dayao; Ronald J Lukas; Jie Wu; Fu-Dong Shi
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

8.  Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension.

Authors:  Sailesh C Harwani; Mark W Chapleau; Kevin L Legge; Zuhair K Ballas; François M Abboud
Journal:  Circ Res       Date:  2012-08-17       Impact factor: 17.367

Review 9.  Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery.

Authors:  Henry A Lester; Cheng Xiao; Rahul Srinivasan; Cagdas D Son; Julie Miwa; Rigo Pantoja; Matthew R Banghart; Dennis A Dougherty; Alison M Goate; Jen C Wang
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

Review 10.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.